The Proteomics of Precision – with Jennifer Van Eyk - Scorecard - MDSpire

The Proteomics of Precision – with Jennifer Van Eyk

Ahead of ISC2026 in Prague, Jennifer Van Eyk explains how scalable LC-MS workflows and single-cell proteomics are helping reveal the biological differences that could make precision medicine a clinical reality

  • By

  • James Strachan

  • Frank van Geel

  • June 17, 2026

  • 5 min

Share

Clinical Scorecard: The Proteomics of Precision – with Jennifer Van Eyk

At a Glance

CategoryDetail
ConditionWomen’s heart health
Key MechanismsSingle-cell proteomics and LC-MS workflows
Target PopulationIndividuals with cardiac diseases, particularly women
Care SettingClinical research and diagnostics

Key Highlights

  • Development of scalable LC-MS pipelines for proteomics
  • Addressing cellular heterogeneity in women's heart health
  • Advancements in remote blood sampling for population studies

Guideline-Based Recommendations

Diagnosis

  • Utilize individual omic signatures for clinically actionable diagnosis

Management

  • Implement individualized therapies based on proteomic data

Monitoring & Follow-up

  • Assess analytical performance at each step of the workflow

Risks

  • Recognize the impact of pathological heterogeneity on health outcomes

Patient & Prescribing Data

Women with cardiac diseases

Therapies should be tailored based on individual cellular heterogeneity

Clinical Best Practices

  • Standardize LC-MS workflows to ensure operational simplicity and robustness
  • Incorporate QC measures in proteomic analyses

Related Resources & Content

Original Source(s)

The Proteomics of Precision – with Jennifer Van Eyk

  • by James Strachan, Frank van Geel

  • June 17, 2026

Related Content

U.S. life expectancy hit an all-time high in 2024, CDC says

3 Medical Routines That Older People May Not Need

“The treatment may be more burdensome than the condition itself."

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.